Major moves to bolster Sandoz’s biosimilars business ahead of its imminent spinoff from parent company Novartis have been revealed by the firm, in the form of a wide-ranging development and manufacturing partnership with Evotec that is potentially worth hundreds of millions of dollars, as well as a further €25m ($27m) investment in Sandoz’s German Holzkirchen site to transform it into a “state-of-the-art biotech lab” by the end of this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?